|
1
|
http://www.diabetesatlas.org/
|
|
2
|
American Diabetes Association, . Diagnosis
and classification of diabetes mellitus. Diabetes Care. 33 Suppl
1:S62–S69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeFronzo RA: Pathogenesis of type 2
diabetes mellitus. Med Clin North Am. 88:787–835, ix. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vigneri P, Frasca F, Sciacca L, Pandini G
and Vigneri R: Diabetes and cancer. Endocr Relat Cancer.
16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Larsson SC, Mantzoros CS and Wolk A:
Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J
Cancer. 121:856–862. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vona-Davis L and Rose DP: Type 2 diabetes
and obesity metabolic interactions: Common factors for breast
cancer risk and novel approaches to prevention and therapy. Curr
Diabetes Rev. 8:116–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng L, Biernacka KM, Holly JM, Jarrett C,
Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP and
Perks CM: Hyperglycaemia confers resistance to chemotherapy on
breast cancer cells: The role of fatty acid synthase. Endocr Relat
Cancer. 17:539–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lipscombe LL, Goodwin PJ, Zinman B,
McLaughlin JR and Hux JE: The impact of diabetes on survival
following breast cancer. Breast Cancer Res Treat. 109:389–395.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiralerspong S, Kim ES, Dong W, Feng L,
Hortobagyi GN and Giordano SH: Obesity, diabetes and survival
outcomes in a large cohort of early-stage breast cancer patients.
Ann Oncol. 24:2506–2514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hou G, Zhang S, Zhang X, Wang P, Hao X and
Zhang J: Clinical pathological characteristics and prognostic
analysis of 1,013 breast cancer patients with diabetes. Breast
Cancer Res Treat. 137:807–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Novosyadlyy R, Lann DE, Vijayakumar A,
Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi
PA, Molinolo AA, et al: Insulin-mediated acceleration of breast
cancer development and progression in a nonobese model of type 2
diabetes. Cancer Res. 70:741–751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gallagher EJ and LeRoith D: The
proliferating role of insulin and insulin-like growth factors in
cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rostoker R, Abelson S, Bitton-Worms K,
Genkin I, Ben-Shmuel S, Dakwar M, Orr ZS, Caspi A, Tzukerman M and
LeRoith D: Highly specific role of the insulin receptor in breast
cancer progression. Endoc-Relat Cancer. 22:145–157. 2015.
View Article : Google Scholar
|
|
15
|
Michels KB, Solomon CG, Hu FB, Rosner BA,
Hankinson SE, Colditz GA and Manson JE: Nurses' Health Study: Type
2 diabetes and subsequent incidence of breast cancer in the Nurses'
Health Study. Diabetes care. 26:1752–1758. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mawson A, Lai A, Carroll JS, Sergio CM,
Mitchell CJ and Sarcevic B: Estrogen and insulin/IGF-1
cooperatively stimulate cell cycle progression in MCF-7 breast
cancer cells through differential regulation of c-Myc and cyclin
D1. Mol Cell Endocrinol. 229:161–173. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rose DP and Vona-Davis L: The cellular and
molecular mechanisms by which insulin influences breast cancer risk
and progression. Endocr-Relat Cancer. 19:R225–R241. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Wang K, Zou QY, Magness RR and Zheng
J: 2,3,7,8-Tetrachlorodibenzo-p-dioxin differentially suppresses
angiogenic responses in human placental vein and artery endothelial
cells. Toxicology. 336:70–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Wang K, Jiang YZ, Chang XW, Dai CF
and Zheng J: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits
human ovarian cancer cell proliferation. Cellular oncology
(Dordrecht). 37:429–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang K, Li Y, Jiang YZ, Dai CF, Patankar
MS, Song JS and Zheng J: An endogenous aryl hydrocarbon receptor
ligand inhibits proliferation and migration of human ovarian cancer
cells. Cancer letters. 340:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Zhao YJ, Zou QY, Zhang K, Wu YM,
Zhou C, Wang K and Zheng J: Preeclampsia does not alter vascular
growth and expression of CD31 and vascular endothelial cadherin in
human placentas. J Histochem Cytochem. 63:22–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li HH, Zhao YJ, Li Y, Dai CF, Jobe SO,
Yang XS, Li XF, Patankar MS, Magness RR and Zheng J: Estradiol 17β
and its metabolites stimulate cell proliferation and antagonize
ascorbic acid-suppressed cell proliferation in human ovarian cancer
cells. Reprod Sci. 21:102–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shaw LM: The insulin receptor substrate
(IRS) proteins: at the intersection of metabolism and cancer. Cell
Cycle. 10:1750–1756. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Papa V and Belfiore A: Insulin receptors
in breast cancer: Biological and clinical role. J Endocrinol
Invest. 19:324–333. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Belfiore A, Frittitta L, Costantino A,
Frasca F, Pandini G, Sciacca L, Goldfine ID and Vigneri R: Insulin
receptors in breast cancer. Ann N Y Acad Sci. 784:173–188. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hamanaka RB and Chandel NS: Targeting
glucose metabolism for cancer therapy. J Exp Med. 209:211–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bergmann U, Funatomi H, Kornmann M, Beger
HG and Korc M: Increased expression of insulin receptor substrate-1
in human pancreatic cancer. Biochem Biophys Res Commun.
220:886–890. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang Q, Li Y, White MF, Fletcher JA and
Xiao S: Constitutive activation of insulin receptor substrate 1 is
a frequent event in human tumors: Therapeutic implications. Cancer
Res. 62:6035–6038. 2002.PubMed/NCBI
|
|
32
|
Sisci D, Morelli C, Garofalo C, Romeo F,
Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S and
Surmacz E: Expression of nuclear insulin receptor substrate 1 in
breast cancer. J Clin Pathol. 60:633–641. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Molloy CA, May FE and Westley BR: Insulin
receptor substrate-1 expression is regulated by estrogen in the
MCF-7 human breast cancer cell line. J Biol Chem. 275:12565–12571.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mauro L, Salerno M, Panno ML, Bellizzi D,
Sisci D, Miglietta A, Surmacz E and Andò S: Estradiol increases
IRS1 gene expression and insulin signaling in breast cancer cells.
Biochem Biophys Res Commun. 288:685–689. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee AV, Jackson JG, Gooch JL, Hilsenbeck
SG, Coronado-Heinsohn E, Osborne CK and Yee D: Enhancement of
insulin-like growth factor signaling in human breast cancer:
Estrogen regulation of insulin receptor substrate-1 expression in
vitro and in vivo. Mol Endocrinol. 13:787–796. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Blaquiere GE, May FE and Westley BR:
Increased expression of both insulin receptor substrates 1 and 2
confers increased sensitivity to IGF-1 stimulated cell migration.
Endocr Relat Cancer. 16:635–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cesarone G, Garofalo C, Abrams MT,
Igoucheva O, Alexeev V, Yoon K, Surmacz E and Wickstrom E:
RNAi-mediated silencing of insulin receptor substrate 1 (IRS1)
enhances tamoxifen-induced cell death in MCF-7 breast cancer cells.
J Cell Biochem. 98:440–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dearth RK, Cui X, Kim HJ, Kuiatse I,
Lawrence NA, Zhang X, Divisova J, Britton OL, Mohsin S, Allred DC,
et al: Mammary Tumorigenesis and Metastasis Caused by
Overexpression of Insulin Receptor Substrate 1 (IRS1) or IRS-2. Mol
Cell Biol. 26:9302–9314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weng LP, Smith WM, Brown JL and Eng C:
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell
growth by blocking IRS1 phosphorylation and IRS1/Grb-2/Sos complex
formation in a breast cancer model. Hum Mol Genet. 10:605–616.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Whyte J, Bergin O, Bianchi A, McNally S
and Martin F: Key signalling nodes in mammary gland development and
cancer. Mitogen-activated protein kinase signalling in experimental
models of breast cancer progression and in mammary gland
development. Breast Cancer Res. 11:2092009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Santen RJ, Song RX, McPherson R, Kumar R,
Adam L, Jeng MH and Yue W: The role of mitogen-activated protein
(MAP) kinase in breast cancer. J Steroid Biochem Mol Biol.
80:239–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Adeyinka A, Nui Y, Cherlet T, Snell L,
Watson PH and Murphy LC: Activated mitogen-activated protein kinase
expression during human breast tumorigenesis and breast cancer
progression. Clin Cancer Res. 8:1747–1753. 2002.PubMed/NCBI
|
